Arrowhead Pharmaceuticals (ARWR) Current Deferred Revenue (2011 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Current Deferred Revenue came in at $108.5 million in Q1 2026, up 150.86% YoY from $43.3 million in Q1 2025, and down 3.03% on a QoQ basis from $111.9 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Current Deferred Revenue (2011 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 15 years of Current Deferred Revenue data on file, last reported at $108.5 million in Q1 2026.
- Quarterly Current Deferred Revenue rose 150.86% year-over-year to $108.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $108.5 million (up 150.86% YoY) and the FY2025 annual result came in at $2.4 million, changed N/A from the prior year.
- Current Deferred Revenue slipped to $108.5 million in Q1 2026, from $111.9 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $130.0 million in Q3 2022 to a low of $866000.0 in Q3 2023.
- A 4-year average of $59.7 million and a median of $54.8 million in 2022 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2023 — Current Deferred Revenue tumbled 99.33% — and 2026, when it jumped 150.86%.
- Tracing ARWR's Current Deferred Revenue over 4 years: stood at $66.3 million in 2022, then slumped by 98.69% to $866000.0 in 2023, then surged by 12825.29% to $111.9 million in 2025, then fell by 3.03% to $108.5 million in 2026.
- The last three Current Deferred Revenue figures came in at $108.5 million (Q1 2026), $111.9 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 94.60 Mn |
| Mar 31, 2026 | 108.54 Mn |
| Dec 31, 2025 | 111.93 Mn |
| Sep 30, 2025 | 2.40 Mn |
| Jun 30, 2025 | 22.98 Mn |
| Mar 31, 2025 | 43.27 Mn |
| Sep 30, 2023 | 866,000.00 |
| Jun 30, 2023 | 16.91 Mn |
| Mar 31, 2023 | 30.91 Mn |
| Dec 31, 2022 | 66.28 Mn |
| Sep 30, 2022 | 130.05 Mn |
| Jun 30, 2022 | 84.29 Mn |
| Mar 31, 2022 | 97.87 Mn |
| Dec 31, 2021 | 108.65 Mn |
| Sep 30, 2021 | 111.06 Mn |
| Jun 30, 2021 | 150.93 Mn |
| Mar 31, 2021 | 144.88 Mn |
| Dec 31, 2020 | 6.74 Mn |
| Sep 30, 2020 | 19.29 Mn |
| Jun 30, 2020 | 26.27 Mn |